Furthermore, Liu et al. showed that IFN-beta and eukaryotic translation initiation factor 2-alpha kinase 2 can be used as potential therapeutic targets, because of their role in the pathogenesis of MDA5-positive DM-ILD (15). This evidence concerns the gene EIF2AK2 and dermatomyositis.